Palleon Pharmaceuticals scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry. Waltham-based Palleon is a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases. The award reflects Dr. Bertozzi’s deep contributions not only to chemistry but to biology and medicine, including the foundational science underlying Palleon’s first-in-class, […]

Cambridge-based Amylyx Pharmaceuticals has won FDA approval for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease. Relyvrio significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. Relyvrio can be taken as a monotherapy or with existing approved treatments. ALS is […]

Partners Eisai and Biogen announced positive topline results from Eisai’s Phase 3 clinical trial of lecanemab, an investigational drug for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease. Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results. Eisai plans to discuss the data with regulatory authorities […]

Pretzel Therapeutics has launched with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function. “We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction. The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both […]

Founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard, Cambridge-based Photys Therapeutics has launched with $75 million Series A funding. Photyx is advancing phosphorylation inducing chimeric small molecules (PHICS), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to […]

President Biden has appointed Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity. […]

30 Years of the Product Show and so many memories. Check out the photos we have collected from the past shows, find you and your friends in these photos and relive the fun times before we make new memories at the upcoming 2022 Product Show!

Amylyx Pharmaceuticals announced today that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 7 to 2 that the available evidence of effectiveness is sufficient to support approval of the drug the company has developed for the treatment of ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease. The committee’s decision was […]

The 2022 Industry Snapshot newly released  by the Massachusetts Biotechnology Council (MassBio) shows significant growth across the life sciences industry in 2021 in both workforce and real estate and reveals resilience in the face of some notable headwinds. Venture capital funding of the biopharma industry remains strong in 2022 despite a downturn in biopharma stock […]

Watertown-based Forma Therapeutics, a clinical-stage biopharma focused on sickle cell disease (SCD) and rare blood disorders, is being acquired by Novo Nordisk for $1.1 billion. The acquisition includes Forma’s lead development candidate, etavopivat, and is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in hemoglobinopathies, a group of disorders in which […]